Press release content from Globe Newswire. The AP news staff was not involved in its creation.
ImmunOs Therapeutics AG Receives Public Funding from Eurostars and Innosuisse for a Novel .
AKAMPIONApril 12, 2021 GMT
- Company forms international consortium with ProteoGenix SAS and Amsterdam UMC
Schlieren (Zurich Area), Switzerland – April 12, 2021 – ImmunOs Therapeutics AG, a Swiss bio-technology company developing a new class of biologics for the treatment of cancer and autoimmune diseases, announced today that is has received public funding from the European Union’s Eurostars-2 Programme and the Swiss Innovation Agency Innosuisse. The funds have been granted for the development of a pioneering HLA-open conformer-specific antibody to treat chronic inflammatory rheumatic diseases. Research will be conducted by a consortium with ProteoGenix SAS (Strasbourg, France) and Amsterdam University Medical Centres (Amsterdam, The Netherlands).